Austria Breast Cancer Therapeutics Market Report 2022 to 2030

Austria Breast Cancer Therapeutics Market Analysis

$ 3999

Increasing patient support efforts and a strong inventory of drugs for breast cancer is responsible for the growth of Austria's breast cancer therapeutics market from $73 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the year 2022-2030. The market is segmented by therapy, by cancer type, and by distribution channel. UCB Pharma, F. Hoffmann-La Roche, and Puma Biotechnology are some major companies in the Austria breast cancer therapeutics market.

ID: IN10ATPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Austria AUTHOR: Parul Choudhary

Buy Now

Austria Breast Cancer Therapeutics Market Executive Analysis

The Austria breast cancer therapeutics market size is at around $73 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. $4.03 Bn was spent on care services in 2022, and $54.43 Mn has invested annually from 2022 to 2024 on training for the helping professions. In the area of health spending, $3.49 Bn was allocated for COVID vaccinations as well as other initiatives aimed at combating and containing the pandemic. From 2022 onward, reimbursements from lower health insurance premiums are also being accounted for.

In Austria, breast cancer is the most frequently diagnosed malignant disease and the main reason why women die from cancer. Austria stood out in a recent analysis of menopausal status-related trends in breast cancer around the world using data from 1998 to 2012 because an increase in premenopausal incidence was accompanied by declines in postmenopausal incidence, a pattern shared only with the US and Israel. Because different molecular subtypes of female breast cancer exhibit distinct age-specific incidence patterns, pre-, and postmenopausal breast cancers differ in relation to available treatments, risk factors, and survival rates. Although the use of adjuvant endocrine therapy among breast cancer patients significantly improved outcomes in Austria, the risk of disease recurrence persists indefinitely, with more than half of recurrences being discovered beyond the first five years. Tamoxifen and aromatase inhibitors can be administered concurrently as an alternative to the prevailing consensus that aromatase inhibitors are more effective than tamoxifen for the first five years of adjuvant therapy. The addition of extended therapy has led to a 40% longer disease-free survival than the use of a placebo or no extended therapy after initial tamoxifen treatment for 5 years. However, because aromatase inhibitors have been linked to adverse effects that lower patients' quality of life, the length of therapy is a crucial factor. Patients who use these medications, for instance, typically suffer sequelae like hot flushes, arthralgia, and bone pain, in addition to cognitive and behavioral side effects in Austria.

austria breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

The Austria breast cancer therapeutics market is being fuelled by an increase in patient support efforts, a strong inventory of new drugs, and an increase in the incidence of breast cancer. The Austria breast cancer therapeutics market will experience significant demand due to the emergence of innovative therapeutics, the availability of improved diagnostic techniques, and the increase in new alliances.

Market Restraints

Austria's breast cancer therapeutics market expansion will be hampered by the high expense of receiving surgical therapy. Therapeutic side effects will once more pose a threat to the market expansion in Austria. The breast cancer market growth rate will also be hampered by the poor technology infrastructure in Austria.

Competitive Landscape

Key Players

Kwizda (AUT)
Richter Pharma (AUT)
Baxter Healthcare (AUT)
UCB Pharma (AUT)
F. Hoffmann-La Roche
Puma Biotechnology
Genentech
Fresenius kabi
AbbVie

Healthcare Policies and Regulatory Landscape

The Austrian federal government is in charge of the legal system, which includes social health insurance regulation (SHI). SHI funds negotiate contracts with providers and are operationally responsible for outpatient medications, ambulatory care, and rehabilitation. The organization and funding of inpatient and outpatient treatment in hospitals are primarily the responsibility of the states (Länder), who control hospital care in their respective areas of jurisdiction within the parameters established by federal law. Because SHI funds, the federal government, the Länder, and municipalities all contribute to the health budget, financing is uneven and dispersed.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.